Forgot your password?
Fixed dose combination of nivolumab and relatlimab improved progression free survival
Local excision margins larger than 1.0 cm associated with improvements in overall survival
Imsidolimab treatment did not significantly improve over placebo.
IGA response observed in 48.4% of patients treated with abrocitinib 200mg
Late-stage data shows more than 50% of patients achieved complete skin clearance through two years of treatment
Study finds patient overestimation of psoriasis severity is associated with mental health status